EGFR/HER2-IN-16

EGFR/HER2-IN-16 (compound 12K) is an effective dual-target inhibitor of EGFR (IC50=6.15 nM) and HER-2 (IC50=9.78 nM) with anti-tumor activity. EGFR/HER2-IN-16 can inhibit the migration of SK-BR-3 cells, arrest the cell cycle in the G0/G1 phase, and induce apoptosis. EGFR/HER2-IN-16 exhibits good anti-proliferative activity against tumor cell models and has little damage to healthy cells. EGFR/HER2-IN-16 can be used in breast cancer research[1].

Product Specifications

UNSPSC

12352005

Target

Apoptosis; EGFR

Type

Reference compound

Related Pathways

Apoptosis; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/egfr-her2-in-16.html

Smiles

O=C(C1=CC=CC(Br)=C1)N2CCN(C3=CC=CC(NC4=C5C=C(C6=CC=CO6)C=CC5=NC=N4)=C3)CC2

Molecular Formula

C29H24BrN5O2

Molecular Weight

554.44

References & Citations

[1]Shuang Hao, et al. "Design, synthesis and biological evaluation of novel quinazoline-derived EGFR/HER-2 dual-target inhibitors bearing a heterocyclic-containing tail as potential anti-tumor agents." Bioorganic Chemistry (2024) : 107686.